Pneumococcal Vaccines Market Future Challenges & Growth Trends Highlighted Until 2031

Future Market Insights (FMI) delivers the key insights on the global pneumococcal vaccines market in its upcoming report titled “Pneumococcal Vaccines Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018 – 2028”. In terms of revenue, the global pneumococcal vaccines market is projected to register a CAGR of 9.1% over the forecast period.

North America is expected to contribute a high revenue share in the global pneumococcal vaccines market over the forecast period due to increasing healthcare expenditure, favourable reimbursement policies for pneumococcal vaccination and development of new multivalent pneumococcal vaccines. Besides, the out-of-pocket costs of pneumococcal vaccines for patients with Medicare coverage is $0 in North America.

The global pneumococcal vaccines market is segmented based on product type, distribution channel, and regions. Based on the product type the market is segmented into pneumococcal conjugate vaccines and pneumococcal polysaccharide vaccines. The pneumococcal conjugate vaccines product type segment is expected to represent high revenue share in the global pneumococcal vaccines market due to growing number of research and development activities to develop new conjugate vaccines for expanding indications. Based on the distribution channel, the market is segmented into pharmacies, public health agencies, community clinics and other distribution channels. Among all the distribution channels, the public health agencies segment is expected to be the leading segment in the pneumococcal vaccines market. The revenue share of community clinics is expected to increase over the forecast period due to the growing number of community clinics.

Get Report Sample Copy @

Increasing number of the clinical trials for development of the pneumococcal vaccine is expected to provide enormous opportunities for the growth of the pneumococcal vaccines market and fulfil the demand for vaccines for multiple serotypes. Increasing government initiatives to reduce the burden of pneumococcal diseases and public–private partnerships are factors expected to fuel the growth of the pneumococcal vaccines market. Partnerships and collaborations among manufacturers for research and development and vaccine distribution is expected to boost the growth of the pneumococcal vaccines market. Increasing pharmacy-based immunization services for pneumococcal vaccination and the catch up campaigns by the SAGE organization to reduce the prevalence of invasive pneumococcal disease are the major factors expected to impel the growth of the pneumococcal vaccines market. Increasing demand for pneumococcal vaccines due to immunization programs is expected to provide immense opportunities for the growth of the pneumococcal vaccines market. The manufacturers of pneumococcal vaccine have reduced the pricing of the vaccines for Gavi-supported countries, which is expected to boost the demand for pneumococcal vaccines. For instance, in January 2018, Pfizer reduced the price of its PCV-13 4 dose vial vaccine for Gavi-supported countries from US$ 3.05 to US$ 2.95 per dose. Increasing addition of pneumococcal vaccine in national immunization programs is favoring the growth of pneumococcal vaccines market. According to the WHO till 2017, total 138 countries are introduced with pneumococcal vaccines in their national immunization program.

However, low awareness among general population regarding pneumococcal immunization, difference in coverage of established and new vaccine, slower introduction of new pneumococcal vaccines are factors expected to hamper the growth of the pneumococcal vaccines market.

The market for pneumococcal vaccines is consolidated with very few players. Examples of some of the key players identified in the global pneumococcal vaccines market are Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc., and Merck & Co., Inc., among others. Manufacturers are focusing on the partnerships and collaborations for expansion of their geographical presence and development of new pneumococcal vaccines. For example, in 2014 Sanofi SA completed the collaboration with SK Chemical Co. of South Korea to co-develop pneumococcal conjugate vaccines.

Speak To Analyst For Queries about Report @

Market Segmentation

By Product Type:

  • Pneumococcal Polysaccharide Vaccines
  • Pneumococcal Conjugate Vaccines

By Distribution Channel:

  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific Excluding Japan
  • Japan
  • Oceania
  • MEA

Reasons to Buy the report

  • We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.
  • Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.
  • The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.


Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates


For Sales Enquiries:

For Media Enquiries:

Press Release:


Posted on

Leave a Reply

Your email address will not be published. Required fields are marked *